文献速递垂体与肾上腺疾病

肾上腺意外瘤及自主皮质醇分泌患者死亡率的年龄与性别差异:一项国际回顾性队列研究

Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-05-06

这项国际回顾性队列研究纳入3656例肾上腺意外瘤患者,按1 mg地塞米松抑制试验后血清皮质醇水平分层。可能自主皮质醇分泌组(HR 1.52,95%CI 1.19-1.94)和自主皮质醇分泌组(HR 1.77,95%CI 1.20-2.62)的全因死亡率均显著高于无功能腺瘤组;65岁以下女性中自主皮质醇分泌与更高的全因死亡率相关(HR 4.39,95%CI 1.93-9.96)。作者认为在随机干预试验结果可用之前,对多数肾上腺意外瘤患者采取保守治疗似乎是合理的。

要点

  • 可能自主皮质醇分泌和自主皮质醇分泌患者的全因死亡率均显著高于无功能腺瘤患者。
  • 65岁以下女性中自主皮质醇分泌与更高的全因死亡率相关(HR 4.39),男性中未观察到。
  • 高血压、血脂异常和糖尿病在无功能腺瘤中均显著少于可能自主皮质醇分泌和自主皮质醇分泌。

核心结论

  • 皮质醇自主分泌与全因死亡率升高相关,尤其在65岁以下女性中。
  • 在随机干预试验结果可用之前,对多数肾上腺意外瘤患者采取保守治疗似乎是合理的。

研究设计与样本

  • 国际回顾性队列研究(NAPACA Outcome),在16个国家的30个中心开展。
  • 纳入18岁及以上、1996年1月1日至2015年12月31日期间检出直径≥1 cm肾上腺意外瘤且有初诊时1 mg地塞米松抑制试验结果的患者。
  • 排除临床明显激素过多、活动性恶性肿瘤或随访不足36个月的患者。
  • 按过夜1 mg地塞米松抑制试验后0800-0900时血清皮质醇分层:低于50 nmol/L为无功能腺瘤,50-138 nmol/L为可能自主皮质醇分泌,大于138 nmol/L为自主皮质醇分泌。
  • 4374例潜在合格患者中3656例纳入死亡率分析队列(2089例[57.1%]无功能腺瘤、1320例[36.1%]可能自主皮质醇分泌、247例[6.8%]自主皮质醇分泌;2350例[64.3%]女性、1306例[35.7%]男性;中位年龄61岁[IQR 53-68];中位随访7.0年[IQR 4.7-10.2])。

主要发现

  • 随访期间352例(9.6%)患者死亡。
  • 经年龄、性别、合并症和既往心血管事件校正后,全因死亡率在可能自主皮质醇分泌组(HR 1.52,95%CI 1.19-1.94)和自主皮质醇分泌组(HR 1.77,95%CI 1.20-2.62)均较无功能腺瘤组显著升高。
  • 65岁以下女性中,自主皮质醇分泌与无功能腺瘤相比全因死亡率更高(HR 4.39,95%CI 1.93-9.96),男性中未观察到。
  • 高血压在无功能腺瘤组2024例中1186例(58.6%)、可能自主皮质醇分泌组1275例中944例(74.0%)、自主皮质醇分泌组238例中179例(75.2%);血脂异常分别在1999例中724例(36.2%)、1250例中547例(43.8%)、237例中123例(51.9%);任何糖尿病分别在2002例中365例(18.2%)、1250例中288例(23.0%)、232例中62例(26.7%);所有p值<0.001。
  • 心血管代谢合并症在无功能腺瘤中显著少于可能自主皮质醇分泌和自主皮质醇分泌。

临床怎么用

  • 作者认为,在随机干预试验结果可用之前,对多数肾上腺意外瘤患者采取保守治疗似乎是合理的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between cortisol secretion and mortality in patients with adrenal incidentalomas is controversial. We aimed to assess all-cause mortality, prevalence of comorbidities, and occurrence of cardiovascular events in uniformly stratified patients with adrenal incidentalomas and cortisol autonomy (defined as non-suppressible serum cortisol on dexamethasone suppression testing). METHODS: We conducted an international, retrospective, cohort study (NAPACA Outcome) at 30 centres in 16 countries. Eligible patients were aged 18 years or older with an adrenal incidentaloma (diameter ≥1 cm) detected between Jan 1, 1996, and Dec 31, 2015, and availability of a 1 mg dexamethasone suppression test result from the time of the initial diagnosis. Patients with clinically apparent hormone excess, active malignancy, or follow-up of less than 36 months were excluded. Patients were stratified according to the 0800-0900 h serum cortisol values after an overnight 1 mg dexamethasone suppression test; less than 50 nmol/L was classed as non-functioning adenoma, 50-138 nmol/L as possible autonomous cortisol secretion, and greater than 138 nmol/L as autonomous cortisol secretion. The primary endpoint was all-cause mortality. Secondary endpoints were the prevalence of cardiometabolic comorbidities, cardiovascular events, and cause-specific mortality. The primary and secondary endpoints were assessed in all study participants. FINDINGS: Of 4374 potentially eligible patients, 3656 (2089 [57·1%] with non-functioning adenoma, 1320 [36·1%] with possible autonomous cortisol secretion, and 247 [6·8%] with autonomous cortisol secretion) were included in the study cohort for mortality analysis (2350 [64·3%] women and 1306 [35·7%] men; median age 61 years [IQR 53-68]; median follow-up 7·0 years [IQR 4·7-10·2]). During follow-up, 352 (9·6%) patients died. All-cause mortality (adjusted for age, sex, comorbidities, and previous cardiovascular events) was significantly increased in patients with possible autonomous cortisol secretion (HR 1·52, 95% CI 1·19-1·94) and autonomous cortisol secretion (1·77, 1·20-2·62) compared with patients with non-functioning adenoma. In women younger than 65 years, autonomous cortisol secretion was associated with higher all-cause mortality than non-functioning adenoma (HR 4·39, 95% CI 1·93-9·96), although this was not observed in men. Cardiometabolic comorbidities were significantly less frequent with non-functioning adenoma than with possible autonomous cortisol secretion and autonomous cortisol secretion (hypertension occurred in 1186 [58·6%] of 2024 patients with non-functioning adenoma, 944 [74·0%] of 1275 with possible autonomous cortisol secretion, and 179 [75·2%] of 238 with autonomous cortisol secretion; dyslipidaemia occurred in 724 [36·2%] of 1999 patients, 547 [43·8%] of 1250, and 123 [51·9%] of 237; and any diabetes occurred in 365 [18·2%] of 2002, 288 [23·0%] of 1250, and 62 [26·7%] of 232; all p values <0·001). INTERPRETATION: Cortisol autonomy is associated with increased all-cause mortality, particularly in women younger than 65 years. However, until results from randomised interventional trials are available, a conservative therapeutic approach seems to be justified in most patients with adrenal incidentaloma. FUNDING: Deutsche Forschungsgemeinschaft, Associazione Italiana per la Ricerca sul Cancro, Università di Torino.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Deutschbein T, Reimondo G, Di Dalmazi G, et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol. 2022. PMID: 35533704. doi:10.1016/S2213-8587(22)00100-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。